Sandbox/AL: Difference between revisions
No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{ | |||
{{Reteplase}} | |||
{{CMG}}; {{AE}} {{AZ}} | {{CMG}}; {{AE}} {{AZ}} | ||
'''''For patient information, click <u>[[ | |||
{{SB}} | '''''For patient information, click <u>[[Reteplase (patient information)|here]]'''''</u>. | ||
{{SB}} Retavase<sup>®</sup> | |||
==Overview== | ==Overview== | ||
''' | '''Reteplase''' (trade names '''Retavase''', '''Rapilysin''') is a [[thrombolytic drug]], used to treat [[myocardial infarction|heart attacks]] by breaking up the [[clot]]s that cause them. | ||
Reteplase is a recombinant non-glycosylated form of human [[tissue plasminogen activator]], which has been modified to contain 357 of the 527 [[amino acid]]s of the original [[protein]]. It is produced in the [[bacterium]] [[Escherichia coli]].{{citation needed|date=December 2013}} | |||
Reteplase is similar to recombinant human tissue plasminogen activator ([[alteplase]]), but the modifications give reteplase a longer [[half-life]] of 13–16 minutes. Reteplase also binds [[fibrin]] with lower affinity than alteplase, improving its ability to penetrate into clots. | |||
Reteplase was approved by the [[Food and Drug Administration]] in 1996. | |||
==Category== | ==Category== | ||
[[ | [[Thrombolytics]], tissue plasminogen activators. | ||
==FDA Package Insert== | ==FDA Package Insert== | ||
=== | ===Retavase<sup>®</sup>=== | ||
''' | ''' [[Reteplase indications and usage|Indications and Usage]]''' | ||
'''| [[ | '''| [[Reteplase dosage and administration|Dosage and Administration]]''' | ||
'''| [[ | '''| [[Reteplase dosage forms and strengths|Dosage Forms and Strengths]]''' | ||
'''| [[ | '''| [[Reteplase contraindications|Contraindications]]''' | ||
'''| [[ | '''| [[Reteplase warnings and precautions|Warnings and Precautions]]''' | ||
'''| [[ | '''| [[Reteplase adverse reactions|Adverse Reactions]]''' | ||
'''| [[ | '''| [[Reteplase drug interactions|Drug Interactions]]''' | ||
'''| [[ | '''| [[Reteplase use in specific populations|Use in Specific Populations]]''' | ||
'''| [[ | '''| [[Reteplase overdosage|Overdosage]]''' | ||
'''| [[ | '''| [[Reteplase description|Description]]''' | ||
'''| [[ | '''| [[Reteplase clinical pharmacology|Clinical Pharmacology]]''' | ||
'''| [[ | '''| [[Reteplase nonclinical toxicology|Nonclinical Toxicology]]''' | ||
'''| [[ | '''| [[Reteplase clinical studies|Clinical Studies]]''' | ||
'''| [[ | '''| [[Reteplase how supplied storage and handling|How Supplied/Storage and Handling]]''' | ||
'''| [[ | '''| [[Reteplase patient counseling information|Patient Counseling Information]]''' | ||
'''| [[ | '''| [[Reteplase labels and packages|Labels and Packages]]''' | ||
==Mechanism of Action== | ==Mechanism of Action== | ||
Retavase® is a recombinant [[plasminogen activator]] which catalyzes the cleavage of endogenous [[plasminogen]] to generate [[plasmin]]. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action.1,2In a controlled trial, 36 of 56 patients treated for an acute myocardial infarction (AMI) had a decrease in [[fibrinogen]] levels to below 100 mg/dL by 2 hours following the administration of Retavase® as a double-bolus intravenous injection (10 + 10 unit) in which 10 units (17.4 mg) was followed 30 minutes later by a second bolus of 10 units (17.4 mg).3 The mean fibrinogen level returned to the baseline value by 48 hours.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = RETAVASE (RETEPLASE) KIT [EKR THERAPEUTICS, INC.] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e9ae6656-977c-4105-8528-bee664aab27a | publisher = | date = |accessdate = }}</ref> | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category: | [[Category: cardiovascular Drugs]] | ||
[[Category:Drugs]] | [[Category:Drugs]] |
Revision as of 17:50, 7 July 2014
Reteplase |
---|
Retavase® FDA Package Insert |
Indications and Usage |
Dosage and Administration |
Contraindications |
Warnings and Precautions |
Adverse Reactions |
Drug Interactions |
Use in Specific Populations |
Description |
Clinical Pharmacology |
Nonclinical Toxicology |
How Supplied/Storage and Handling |
Labels and Packages |
Clinical Trials on Reteplase |
ClinicalTrials.gov |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
For patient information, click here. Synonyms / Brand Names: Retavase®
Overview
Reteplase (trade names Retavase, Rapilysin) is a thrombolytic drug, used to treat heart attacks by breaking up the clots that cause them.
Reteplase is a recombinant non-glycosylated form of human tissue plasminogen activator, which has been modified to contain 357 of the 527 amino acids of the original protein. It is produced in the bacterium Escherichia coli.[citation needed]
Reteplase is similar to recombinant human tissue plasminogen activator (alteplase), but the modifications give reteplase a longer half-life of 13–16 minutes. Reteplase also binds fibrin with lower affinity than alteplase, improving its ability to penetrate into clots.
Reteplase was approved by the Food and Drug Administration in 1996.
Category
Thrombolytics, tissue plasminogen activators.
FDA Package Insert
Retavase®
Indications and Usage | Dosage and Administration | Dosage Forms and Strengths | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Use in Specific Populations | Overdosage | Description | Clinical Pharmacology | Nonclinical Toxicology | Clinical Studies | How Supplied/Storage and Handling | Patient Counseling Information | Labels and Packages
Mechanism of Action
Retavase® is a recombinant plasminogen activator which catalyzes the cleavage of endogenous plasminogen to generate plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action.1,2In a controlled trial, 36 of 56 patients treated for an acute myocardial infarction (AMI) had a decrease in fibrinogen levels to below 100 mg/dL by 2 hours following the administration of Retavase® as a double-bolus intravenous injection (10 + 10 unit) in which 10 units (17.4 mg) was followed 30 minutes later by a second bolus of 10 units (17.4 mg).3 The mean fibrinogen level returned to the baseline value by 48 hours.[1]